Spots Global Cancer Trial Database for A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects
Official Title: A Randomized, Open-label, Four-sequence, Four-period, Crossover, Single Dosing, Phase 1 Clinical Trial to Compare the Safety, Tolerability, and Pharmacokinetics of SOL-804 and Zytiga in Healthy Male Subjects
Study ID: NCT06014853
Conditions
Study Description
Brief Summary: Study Design : A randomized, open-label, four-sequence, four-period, crossover, single dosing, phase 1 study
Detailed Description: To evaluate the safety, tolerability and pharmacokinetic characteristics of SOL-804-F and Zytiga tablets following a single oral dose and Zytiga 1,000 mg in healthy male volunteers.
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: SeungHwan Lee
Affiliation: Seoul National University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
